Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China’s NMPA accepts Legend Biotech’s NDA for cilta-cel
The phase 2 clinical study assessed the efficacy and safety of cilta-cel in adult patients with relapsed or refractory multiple myeloma. Credit: Doodlart from Pixabay.
The phase 2 clinical study assessed the efficacy and safety of cilta-cel in adult patients with relapsed or refractory multiple myeloma. Credit: Doodlart from Pixabay.